Nature.com Scientific Reports http://dx.doi.org/10.1038/s41598-017-13189-3
Jane Maddock1'2, Ang Zhou3, Alana Cavadino2'4, Elzbieta Kuzma5, Yanchun Bao6, Melissa C. Smart6, Kai-Uwe Saum7, Ben Schottker7,8,9, Jorgen Engmann10, Marie Kjffirgaard11,12, Ville Karhunen13,14,Yiqiang Zhan15, Terho Lehtimaki16, Suvi P. Rovio17, Liisa Byberg18, Jari Lahti19,20, Pedro Marques-Vidal 21, Abhijit Sen22, Laura Perna7, Henrik Schirmer23,24, Archana Singh-Manoux10,25, Juha Auvinen13,14, Nina Hutri-Kahonen26,
Mika Kahonen27, Lena Kilander28, Katri Raikkonen19, Hakan Melhus29, Erik Ingelsson29,30, Idris Guessous 31,32,33, Katja E Petrovic34, Helena Schmidt35, Reinhold Schmidt36, Peter Vollenweider21, Lars Lind29, Johan G. Eriksson37,38, Karl Michaelsson18, Olli T. Raitakari17,39, Sara Hagg15, Nancy L. Pedersen15, Karl-Heinz Herzig40,41,42,43, Marjo-Riitta Jarvelin13,44, Juha Veijola42,45,46, Mika Kivimaki 10,47, Rolf Jorde11,12, Hermann Brenner7,8, Meena Kumari6,10, Chris Power2, David J. Llewellyn5 & Elina Hypponen3,2 8
- This study noticed that 800 IU of vitamin D did not help, and extrapolated that higher vitamin D would not help
Mendelian randomization Wikipedia
M.R. only works if there are some high-enough levels to work from
- This study also strangely considered only 2 of the 6 well-known vitamin D related genes
The study ignored the importance of the Vitamin D Receptor on Cognition (see below)
A 7th gene, Pdia3, may be more important in the brain than the Vitamin D Receptor
- Alzheimer’s 4X less likely with high level of vitamin D – 2 studies April 2012
- Alzheimer’s cognitive decline is 3X faster if low vitamin D – May 2017
- Brain may deal with all forms of Vitamin D (rat brain) – Sept 2017
Alzheimers-Cognition - Overview has the following summary
- FACT: Cognitive decline is 19X more likely if low vitamin D
- FACT: Dementia is associated with low vitamin D levels.
- FACT: Alzheimer’s 21 % more likely if low vitamin D
- FACT: Alzheimer's Disease is 4X less likely if less likely if high vitamin D
- FACT: Every single risk factor listed for Alzheimer's Disease is also a risk factor for low vitamin D levels
- FACT: Elderly cognition gets worse as the elderly vitamin D levels get even lower (while in senior homes)
- OBSERVATION: Reports of increased vitamin D levels result in improved cognition
- OBSERVATION: Alzheimer’s patients 3X more likely to have a malfunctioning vitamin D receptor gene – 2012
- OBSERVATION: Alzheimer's Disease has been seen to halt when vitamin D was added.
- OBSERVATION: 39 vitamin D and Alz. or Cognition lntervenion trials as of Sept 2018
- OBSERVATION: 2 Meta-analysis in 2012 agreed that Alzheimer's Disease. associated with low vitamin D
- OBSERVATION: 50X increase in Alzheimer's while decrease in vitamin D
- OBSERVATION: Vitamin D reduces Alzheimer’s disease in 11 ways
- OBSERVATION: Alzheimer’s cognition improved by 4,000 IU of vitamin D
- OBSERVATION: Plaque removed in mice by equiv. of 14,000 IU daily
- FACT: Vitamin D is extremely low cost and has very very few side effects
- CONCLUSION: Everyone concerned about cognitive decline or Alzheimer's Disease should take vitamin D
- PREDICTION: By 2021 Magnesium, Omega-3 and high dose Vitamin D will be found to reverse Alzheimer's in humans
- As of 2018 that combination has worked well with Multiple Sclerosis, Sleep, and Cluster Headaches
- All items in category Cognition and vitamin D
Overview Schizophrenia and Vitamin D contains the following summary
Many reasons to think that schizophrenia is associated with low vitamin D
1) 97% of patients with schizophrenia are vitamin D deficient
2) Schizophrenia varies with latitude (UVB) by 10X (controversy)
3) Schizophrenia is more common in those with dark skin (when away from the equator)
4) Schizophrenia is associated with low natal vitamin D
5) Schizophrenia has been increasing around the world when vitamin D has been decreasing (controversy)
6) Schizophrenia is associated with low birth rate, which is associated with low vitamin D
7) Schizophrenia is associated with Autism which is associated with low vitamin D
8) Schizophrenia Bulletin Editorial (Jan 2014) speculated that Vitamin D could be a major player
9) Schizophrenia 2X more likely if low vitamin D - meta-analysis
10) Schizophrenia increased 40 % for Spring births after Danes stopped vitamin D fortification
11) Schizophrenia is associated with season of birth
12) Schizophrenia is associated with poor Vitamin D Receptor genes
13) Schizophrenia risk is decreased if give Vitamin D after birth
Click here for some details
Omega-3 may treat schizophrenia wonder if Omega-3 and Vitamin D would be additive or even synergistic
Items in both VitaminDWiki categories Cognition and Genetics are listed here:
- 8 genes associated with both Alzheimer’s and lowish Vitamin D – May 2019
- Body may changes gene activation if more Vitamin D is needed by tissue (Schiz. in this case) – Oct 2018
- Study concluded cognitive problems are not a result of low vitamin D (many studies disagree) Nov 2017
- Genes which reduce blood-level vitamin D increase the risk of Alzheimer’s disease – Dec 2016
- Less vitamin D generated from sunlight by schizophrenia patients – 2016
- Schizophrenia and vitamin D have latitude-related genes – Nov 2010
Items in BOTH the categories Cognition and Vitamin D Receptor Gene
- Alzheimer’s (1.2X) and Parkenson’s (1.3X) more likely if poor Vitamin D Receptor – meta-analysis March 2019
- Treating herpes reduced incidence of senile dementia by 10 X (HSV1 reduces VDR by 8X) – 2018
- Body may changes gene activation if more Vitamin D is needed by tissue (Schiz. in this case) – Oct 2018
- Alzheimer’s associated with Vitamin D and Vitamin D receptor – video and pdf – Aug 2018
- Cerebral small vessel disease 2.5 X more likely if poor Vitamin D Receptor – Sept 2018
- Alzheimer’s Disease is associated with genes which restrict vitamin D – Aug 2015
- Parkinson's and Alzheimer's: associations with vitamin D receptor genes and race – meta-analysis July 2014
- Alzheimer’s patients 3X more likely to have a malfunctioning vitamin D receptor gene – 2012
- Alzheimer’s patients are genetically 70 percent more likely to be vitamin D in-efficient – Feb 2012
Items of Cognition and Intervention (give Vitamin D and see what happens)
- Schizophrenia reduced by biweekly 50,000 IU Vitamin D and probiotics – RCT Feb 2019
- Cognitive function of adult women in Turkey improved in 3 months with 3 dollars of Vitamin D – not an RCT Jan 2019
- Amyloid brain plaque both prevented and removed by high vitamin D (in mice) – Aug 2018
- Cognition improved a tiny amount with 400 IU of vitamin D (not a surprise) – RCT Oct 2018
- 9,000 dollar prize for RCT which found cognition improved after taking 4,000 IU of Vitamin D for 18 weeks – May 2018
- Senior cognition improved somewhat by 4,000 IU of Vitamin D (if initially less than 30 ng) – RCT April 2017
- Vitamin D and Glutamine reduced Trauma Center deaths by half – March 2017
- Mental health intervention trials using enough vitamin D for long enough found benefits – Jan 2017
- Visual memory improved a bit by vitamin D if start with less than 30 ng – RCT Jan 2017
- Cognition of Alzheimer’s patients improved by daily 4,000 IU of vitamin D – RCT Jan 2015
- 2,000 IU of vitamin D reduced schizophrenia chance by 77 percent (male infants) - 2004
- Better memory if take lots of vitamin D (senior rats) – May 2015
- Severe Alzheimer's delayed by 1 year with vitamin D intervention – March 2014
- Vitamin D aided progesterone in reducing traumatic brain injury – RCT Dec 2012
- Age-related cognitive decline in rats mitigated by Vitamin D intervention – RCT Oct 2012
Items of Cognition and Meta-analysis
- Alzheimer's risk increased 7 percent for every 4 ng decrease in Vitamin D– meta-analysis Nov 2018
- Poor cognition 26 percent more likely if low Vitamin D (29 studies) – meta-analysis July 2017
- Dementia risk factor is increased by 1.5 if low vitamin D – meta-analysis Jan 2017
- Omega-3 helps childhood cognition – meta-analysis April 2016
- Poor cognition associated with low vitamin D in elderly (Asians now too) – meta-analysis March 2016
- Cognitive decline in elderly slowed by Omega-3 – meta-analysis May 2015
- Alzheimer’s disease 21 percent more likely if low vitamin D – meta-analysis Aug 2015
- Parkinson's and Alzheimer's: associations with vitamin D receptor genes and race – meta-analysis July 2014
- Brain (Alzheimer’s) worked better with Vitamin D intervention – meta-analysis July 2013
- Alzheimer’s and Parkinson’s diseases associated with low vitamin D – meta-analysis June 2013
- Alzheimer's Disease more likely with low vitamin D – meta-analysis Oct 2012
- Alzheimer disease associated with 2.5 ng less vitamin D – meta-analysis Sept 2012
- Cognitive Impairment 2.4X more likely if low vitamin D – meta-analysis July 2012
The causal nature of the association between hypovitaminosis D and poor cognitive function in mid- to later-life is uncertain. Using a Mendelian randomisation(MR) approach, we examined the causal relationship between 25(OH)D and cognitive function. Data came from 172,349 participants from 17 cohorts. DHCR7(rs12785878), CYP2R1 rs12794714) and their combined synthesis score were chosen to proxy 25(OH)D. Cognitive tests were standardised into global and memory scores. Analyses were stratified by 25(OH)D tertiles, sex and age. Random effects meta-analyses assessed associations between 25(OH)D and cognitive function. Associations of serum 25(OH)D with global and memory- related cognitive function were non-linear (lower cognitive scores for both low and high 25(OH)D, Pcurvature < 0.006), with much of the curvature attributed to a single study. DHCR7, CYP2R1, and the synthesis score were associated with small reductions in 25(OH)D per vitamin D-decreasing allele. However, coefficients for associations with global or memory-related cognitive function were nonsignificant and in opposing directions for DHCR7 and CYP2R1, with no overall association observed for the synthesis score. Coefficients for the synthesis score and global and memory cognition were similar when stratified by 25(OH)D tertiles, sex and age. We found no evidence for serum 25(OH)D concentration as a causal factor for cognitive performance in mid- to later life.
The profound effect of an ageing population is evidenced by estimates suggesting 65-7 million people worldwide will be affected by dementia by 2030, increasing to 115-4 million by 2050 1. The latency period from the onset of symptoms to clinical diagnosis is typically very long and cognitive changes can be observed decades before diagnosis2. So, for the development of efficient primary prevention strategies, it is essential to identify risk factors that operate at the early pre-clinical stage.
Hypovitaminosis D is hypothesised to be one such risk factor. Low 25-hydroxyvitamin D [25(OH)D] levels are prevalent in older individuals 3, and adults with cognitive difficulties have been shown to have hypovitaminosis D 4-6. There is a biologically plausible link between vitamin D and cognitive function. The vitamin D receptor (VDR), vitamin D metabolites and enzymes required for vitamin D activation have been found in the brain and central nervous system7. Additionally, experimental studies have demonstrated that active vitamin D may influence brain and neuron development 8, and have neuroprotective potential and antioxidant effects 7. Studies on VDR knockout mice have demonstrated that hypovitaminosis D may play a role in accelerated ageing, behavioural, social, motor and sensory deficits9-12, all of which can contribute to cognitive decline.
A number of observational studies have linked hypovitaminosis D with cognitive impairment and/ or dementia 5,6,13,14. In 2012, a meta-analysis including eight cross-sectional studies (n = 2,740) found that mean scores on the Mini-Mental State Examination (MMSE) were lower among individuals with <50 nmol/l compared with >50 nmol/l 25(OH)D5. The authors also demonstrated that 25(OH)D concentrations were on average 6-2 nmol/l lower in Alzheimer’s disease patients compared with controls (n = 502)5. Another meta-analysis in 2012, including five cross-sectional and two longitudinal studies (n = 7,688) suggested that the risk of cognitive impairment was doubled in participants with low vitamin D status compared to those with normal levels6. A systematic review in 2013 found that low vitamin D status was associated with worse cognitive function or a higher incidence of dementia in 72% of the 25 cross-sectional studies and 67% of the six prospective studies included13. In 2017, a meta-analysis including five longitudinal studies supported the hypothesis that 25(OH)D concentrations <25 nmol/l may contribute to the development of dementia14.
Results from randomised controlled trials (RCTs) have not been as promising 15-18. However, null findings from these trials may be due to a number of reasons including: short follow-up time16,18, inclusion ofyounger participants16, inclusion of supraphysiological doses18, vitamin D being used in combination with other substances15,17, in low doses17 or, high baseline 25(OH)D status15,16.
In light of these findings, in 2014 a group of international experts came to the consensus that hypovitaminosis D should be considered a risk factor for cognitive decline and dementia as it may change the clinical presentation of dementia due to accompanying comorbidities, but that 25(OH)D should not be used as a diagnostic or prognostic biomarker 19. The authors concluded that vitamin D supplementation should be part of the care management of older adults with cognitive disorders 19. However, whether vitamin D plays a causal role in cognitive decline directly or through its impact on comorbidities, or whether it is a consequence of cognitive decline remains unclear.
Determining the nature of the true relationship between vitamin D and cognitive function is challenging due to study design issues. For instance, even if well-conducted, observational studies may not capture all unmeasured confounding and there is a possibility of reverse causality 20. RCTs are the gold standard approach for inferring a causal association, but they also have their limitations 20. Mendelian Randomisation (MR) is an approach that uses a genetic variant, which is associated with the exposure of interest, to estimate the causal relationship between an exposure and outcome 20.
Table 1. Participant characteristics. IQR: Interquartile range; MAF: minor allele frequency. 1958BC: 1958 British birth cohort; COLAUS: The Colaus study; ESTHER: Epidemiologische Studie zu Chancen der Verhutung, Fruherkennung und optimierten Therapie chronischer Erkrankungen in der alteren Bevolkerung; HBCS: Helsinki Birth Cohort Study; NFBC66: Northern Finland birth cohort 1966; PIVUS: The Prospective Investigation of the Vasculature in Uppsala Seniors; TROMSO: The Tromso Study; ULSAM: Uppsala Longitudinal Study of Adult Men; YFS: Young Finns; ASPS: Austria Stroke Prevention Study; ELSA: English Longitudinal Study of Ageing; HRS: Health and Retirement Study; STR: Swedish Twin Registry; TwinGene: Swedish Twin Registry; UKBiobank: UK Biobank; UKHLS: The UK Household Longitudinal Study (Understanding Society); WII: Whitehall II * N’s based on participants with cognitive data.
This method can help to overcome some limitations of observational studies as it relies on the random assignment of genetic variants from parents to offspring to reduce the possibility of confounding20. Furthermore, since the genetic variant is established at conception, the possibility ofreverse causality is minimised20. If hypovitaminosis D is causally related to worse cognitive function, the genetic variant associated with vitamin D status, should be associated with cognitive function. Using an MR approach, a recent study provided some support for a beneficial role of 25(OH)D in reducing the risk of dementia21.
We conducted a study to examine the causal nature of the association between vitamin D status, as measured by 25(OH)D, and cognitive function in mid- to later-life using a MR approach.
Participants. Information came from 17 cohorts: 1958 British birth cohort (1958BC); Austria Stroke Prevention Study (ASPS); The CoLaus Study (CoLaus); English Longitudinal Study of Ageing (ELSA); Epidemiologic study assessing prevention, early detection, and treatment of chronic diseases among older adults (ESTHER); Helsinki Birth Cohort Study (HBCS); Health and Retirement Study (HRS); Northern Finland Birth Cohort 1966 (NFBC1966); The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS); Swedish Twin Registry (STR); The Tromso Study (Tromso); TwinGene; UK Biobank; The UK Household Longitudinal Study (UnderstandingSociety, UKHLS); Uppsala Longitudinal Study of Adult Men (ULSAM); Whitehall II (WII); and Young Finns Study (YFS). In all studies, data were restricted to White/European participants with genetic and cognitive data (n = 172,349, Table 1). Information on 25(OH)D concentrations was available in nine studies (n = 26,856). All participants provided informed consent and ethical approval was granted by local research ethics committees. An expanded description is provided in supplementary text.
Genetic variants. We used two single nucleotide polymorphisms (SNPs) based on their demonstrated associations with 25(OH)D concentrations: rs12785878 (vitamin D-decreasing allele, G), located near gene coding 7-dehydrocholesterol reductase (DHCR7), and rs12794714 (vitamin D-decreasing allele, A) near 25-hydroxylase (CYP2R1)22,23. When these SNPs were not accessible, proxy SNPs in perfect linkage disequilibrium were used (Supplementary Table 1). The assumptions for the use of these SNPs to proxy vitamin D status in MR studies have been assessed in a previous study using data from 1958BC24. Data on DHCR7 and CYP2R1 were available in all cohorts. For analysis purposes, both DHCR7 and CYP2R1 genotypes were coded as 0-2 depending on presence of alleles associated with decreasing 25(OH)D concentrations, where homozygous genotypes were coded as 2. A score was created by summing DHCR7 and CYP2R1 on the basis of their effect alleles24. The score is referred to as the synthesis score since it contains the SNPs involved in the synthesis of 25(OH)D24. The few participants with 3 or 4 25(OH)D-decreasing alleles (ranging from 9-6% in 1958BC to 17-4% in Troms0) were grouped. Genotyping techniques are described in supplementary materials. Quality checks of each SNP including minor allele frequencies and Hardy Weinberg equilibrium are reported in Supplementary Table 1. Minor allele frequencies were compared with HapMap data and were found to be approximately similar.
25-Hydroxyvitamin D. 25(OH)D concentrations were available for nine studies, with details for measurement methods provided in the supplementary text. In order to examine analyses stratified by 25(OH)D concentrations, sex and study specific 25(OH)D tertiles(T) were created (Supplementary Table 2). 25(OH)D was found to be skewed, therefore natural log (ln) transformation was applied to approximate a normal distribution when 25(OH)D was the outcome in analyses.
Global and memory cognitive function. Details of cognitive tests in each cohort, grouped to represent global and/or memory cognitive function, can be found in supplementary materials. Each test was standardised to produce a mean of zero and a standard deviation of one. To obtain a summary score for global/memory cognitive function, relevant tests were summed and re-standardised. ULSAM and CoLaus had information on global cognitive function only.
Covariates. Results in all studies were adjusted for sex, age (in years), month of blood collection for 25(OH) D, and, education and depressive symptoms which were considered potential confounders a priori. A description of how education and depressive symptoms were measured in each cohort is outlined in supplementary materials.
Statistical analyses. Within each study, linear regression models were used to assess the following: 1) phenotypic associations i.e. serum 25(OH)D and cognitive function adjusted for age, sex, month of 25(OH) D blood collection, educational attainment and depressive symptoms where possible; 2) associations between SNPs/synthesis score and cognitive function adjusted for age, sex, education, depressive symptoms and principle components (to account for population stratification) where specified in supplementary materials. The presence of non-linear phenotypic associations were assessed by including a quadratic term of 25(OH)D in the regression model. Interaction by age and sex was also assessed.
Results from within-study analyses were combined using random effects meta-analyses. Analyses were stratified by 25(OH)D-tertiles, sex and age (<65 years vs. >65 years). I-square tests were used to indicate heterogeneity between cohorts.
Meta-regression was used to examine heterogeneity between the cohorts using results from the meta-analysed phenotypic analyses. Study characteristics that were hypothesised a priori to affect the association included sex, age (<65 years vs. >65 years), vitamin D assay (mass spectrometry or immunoassay) and country region [categorised as UK, Nordic (Finland, Sweden, Norway), central Europe (Austria, Germany, Switzerland) and the US].
To examine the strength and suitability of the SNPs/synthesis score as instruments for MR studies, associations between the SNPs/synthesis score and ln25(OH)D (adjusted for age, sex, month of 25(OH)D collection and study-specific components where specified) were examined, and F-statistics were calculated. The F-statistic was approximated from the proportion of variation in the model (R2) assessing 25(OH)D which is explained by the SNPs/synthesis score [F-stat = (R2*(n — 2))/(1 — R2)]. The adjusted R2 in each cohort was weighted by the sample size of each cohort. The F-statistic should ideally be greater than ten in order for an instrument to be considered strong enough to use 25.
Participants from UK Biobank were used to investigate cognitive domain-specific effects (using standardised fluid intelligence, pairs matching and reaction time tests) of the SNPs/synthesis score.
Finally, a power calculation was conducted to determine the smallest effect size that our study able to detect at a two-sided alpha level of 0-05 and at a power of 0.80. Power analysis was performed using Quanto 1.2 (University of Southern California, USA).
Meta-analyses were conducted at the Centre for Population Health Research (University of South Australia) using STATA version 14.
A total of 172,349 participants had complete data for the SNPs and completed at least one cognitive test. Participants from eight cohorts had no information on 25(OH)D concentrations, while two studies had no information on memory-related cognitive function. Basic characteristics of all studies are presented in Table 1.
Phenotypic association between serum 25(OH)D and cognitive function.
In meta-analyses ofthe nine eligible studies, there was no evidence of interaction by sex or age on phenotypic associations (p > 0-06, Supplementary Table 3). There was evidence of a non-linear relationship between serum 25(OH)D and cognitive function, p < 0-006 (Supplementary Table 3) after adjustment for age, sex, month of blood collection, educational attainment and depressive symptoms. However, this non-linear association was driven by a single study and weakened following its’ exclusion from the meta-analyses (Table 2). When stratified by 25(OH)D tertiles, participants in T2 and T3 had higher scores in global cognition compared with those in T1 (0-05 SD, 95%CI 0-01, 0-09; p = 0-02 and 0-07 SD, -0-01, -0-15; p = 0-07, respectively), while no clear differences were not seen for memory cognition (P > 0-11 for both comparisons). There were no overall differences in phenotypic associations by sex, country or vitamin D assay, while associations appeared somewhat stronger among those aged 65 years or above compared to younger participants (Supplementary Table 4).
Table 2. Association of sex-specific 25(OH)D tertiles with cognition. ‘excluding 1958BC, pcurvature = 0-04; f excluding 1958BC, pcurvature = 0-16.
Figure 1. Association of CYP2R1, DHCR7 and synthesis score with global and memory cognition.
Figure 2. Association of CYP2R1, DHCR7 and synthesis score with 25-hydroxyvitamin D (25(OH)D).
Mendelian randomisation: association between SNPs/synthesis score and cognitive function.
There were no associations between 25(OH)D-related SNPs/synthesis score with global or memory cognition (Fig. 1, Supplementary Table 5). Furthermore, there was no evidence for an association between SNPs/synthesis score with either cognitive measure stratifying by sex, age and 25(OH)D tertiles (Supplementary Figure 1). Genetic associations with cognitive function did not vary by age, sex or country (Supplementary Table 4).
Information for pairs matching (n = 110,545), reaction time (n = 109,911), reasoning (n = 35,603), and prospective memory (n = 36,311) was available for the UK Biobank. We conducted domain specific analyses against all the four outcomes, but observed no associations with the SNPs/synthesis score (Supplementary Figure 2).
Instrument validation: association between SNPs/synthesis score and 25(OH)D.
The SNPs/synthesis score were associated with 25(OH)D (Fig. 2, Supplementary Table 6). 25(OH)D concentrations were 2-7% (95% CI 0-7% to 4-1%), 3-3% (95% CI 0-5% to 4-3%), and 3-1% (95% CI 0-5% to 4-0%) lower per vitamin D-decreasing allele for DHCR7, CYP2R1 and the synthesis score respectively. The weighted F-statistic was 54-13 (R2 = 0.003), 71-69 (R2 = 0.004) and 113-50 (R2 = 0.006) for DHCR7, CYP2R1 and the synthesis score respectively. Since these F-statistics are > 10, the SNPs/'synthesis score can be considered strong proxies for 25(OH)D in MR analyses25.
Power calculation. With a sample size of 153,187, a power of 0-80, and a two-sided alpha level of 0-05, we are sufficiently powered to detect a 0-0125 SD change in the cognitive score per vitamin D-decreasing allele. For the smallest stratum with n = 4,957, our study is powered to detect an effect size of0-058 SD or larger (Supplementary Table 7). Converted to the reflect the association between serum 25(OH)D and a standardised cognitive outcome, this corresponds to a 0.09 SD and 0.51 SD difference by 1 SD change in log 25(OH)D for the full and minimum sample, respectively.
Using data from 17 studies with information for up to 172,349 participants, we failed to find any evidence for a causal association between vitamin D and cognitive function, with sub-group analyses stratifying by age, sex and 25(OH)D tertiles providing a consistent lack of evidence for causality. These findings suggest that the non-linear phenotypic association between serum 25(OH)D and cognitive function (where cognitive scores were lower for both low and high 25(OH)D concentrations), which was also confirmed in our datasets, may be due to reverse causation or confounding.
There are a limited number of RCTs assessing the effect of vitamin D supplementation on cognitive function15-18. In line with our study, these have provided little evidence for causality. In particular, our MR findings were supportive of results from the biggest RCT to date which was carried out among older women (>65 years, n = 4,143) participating in the Women’s Health Initiative15. In that RCT, over a mean follow-up of 7-8 years, there was no effect of supplementation with 400 IU/day vitamin D3 and 1,000 mg/day calcium on cognitive impairment. However, it has been argued that the inclusion of calcium, which can be harmful for the brain, may have weakened the result, and baseline concentrations of 25(OH)D among participants may have been adequate to meet their cognitive requirements26. Two pre-post studies have been conducted 27,28. One found no effect of four weeks of vitamin D2 supplementation on cognitive function among institutionalised older adults27. In contrast with our findings, the other study demonstrated an improvement in the cognitive performance among 20 older adults after 16 months of 800 IU/day vitamin D3 supplementation compared with controls (n = 24)28. However, the non-random pre-post design of these studies is a limitation as potential unmeasured confounding cannot be ruled out.
One earlier genetic study suggested a beneficial effect of 25(OH)D on reducing the risk of Alzheimer’s disease21. However, in this study the beneficial association with Alzheimer’s disease was due to a significant association with a variant in the GC gene coding variations in the vitamin D binding protein, while in line with our study, no associations were seen for DHCR7, or CYP2R1. As we have described earlier, while associated with 25(OH) D concentrations, GC is not suitable for the use as its’ proxy marker in Mendelian randomisation analyses, given likely influences on bioavailability of 25(OH)D29. Indeed, the success of an MR study relies upon the ability of the genetic variant to accurately proxy the exposure of interest20. In line with previous studies 22-24 we used two variants which have been consistently associated with circulating 25(OH)D concentrations. Both variants are located upstream of the 25(OH)D metabolite, with DHCR7 influencing substrate availability and CYP2R1 coding the 25-OH-hydroxylate. Analyses stratifying by 25(OH)D concentrations suggested that the association between CYP2R1 and 25(OH)D is restricted to participants with the highest group. While this could suggest that the CYP2R1 variant has a rate-limiting effect on 25(OH)D synthesis for individuals with the high 25(OH) D concentrations, it is also possible that the apparent difference is due to the wide range of 25(OH)D concentrations for individuals in the highest tertile in this study. Stratification by 25(OH)D tertiles could also have led to collider bias, i.e. when the association of two variables (i.e. genetic variant and cognitive function), changes upon conditioning on a third variable (i.e. 25(OH)D), when this third variable is affected by the other two. Therefore, cautious interpretation is required when stratifying MR analyses by 25(OH)D.
Interpreting the association between vitamin D and cognitive function is complicated. Dementia is often accompanied by a range of other chronic diseases/disorders, where cognitive decline may enhance chronic disease and vice-versa19. Vitamin D supplementation has been shown to reduce mortality risk30. Hypovitaminosis D has been associated with a number of conditions including osteoporosis, vascular disease and reduced olfactory function31, which can precipitate the progression of dementia. Therefore it is plausible that the potential cognitive benefits of vitamin D identified in observational studies may be mediated by improvements in accompanying chronic diseases.
Results should be interpreted with limitations in mind. It has been suggested that there are sensitive periods i.e. foetal development, growth and senescence during which vitamin D is ofparticular significance to neurocognition19. Our study looked at effects on cognitive function in mid- to later-life, and while we found no evidence stratifying by age group (i.e. <65 versus >65 years), we could not assess the association in younger or very old individuals. Nevertheless, the use of genetic variants to proxy 25(OH)D status assumes that we have represented lifetime 25(OH)D status20. Generalisability of the study results is restricted to caucasian populations. Cognition was assessed using different tests between the cohorts therefore a composite measure of global cognitive function was used to obtain a more uniform representation of cognitive function; this may have masked some domain specific effects. Since our previous study emphasised the role of vitamin D in cognitive function, a separate memory function score was created to account for any discriminating effects of vitamin D32. A recent study suggested that vitamin D may be associated with speed of processing and executive functioning33, we found no evidence for domain-specific effects using data from UK Biobank. MR studies require large sample sizes partly due to the very small amount of variation in the exposure explained by genetic instruments20. According to the power calculation, our study was sufficiently powered to detect relatively small effects. Nevertheless, it should be acknowledged that our analyses may have been underpowered to detect small causal effects operating at the extremes of 25(OH) D distribution.
We found no evidence for a causal association between 25(OH)D concentrations and cognitive performance in mid- to later-life.
- Prince, M. et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer’s & Dementia 9, 63-75. e62 (2013).
- Smith, A. D. Imaging the progression of Alzheimer pathology through the brain. Proceedings of the National Academy of Sciences of the United States of America 99, 4135-4137, https://doi.org/10.1073/pnas.082107399 (2002).
- Annweiler, C. & Beauchet, O. Vitamin D in older adults: the need to specify standard values with respect to cognition. Frontiers in aging neuroscience 6, 72 (2014).
- Annweiler, C. et al. Vitamin D and cognitive performance in adults: a systematic review. European Journal of Neurology 16, 1083-1089 (2009).
- Balion, C. et al. Vitamin D, cognition, and dementia A systematic review and meta-analysis. Neurology 79, 1397-1405 (2012).
- Etgen, T., Sander, D., Bickel, H., Sander, K. & Forstl, H. Vitamin D deficiency, cognitive impairment and dementia: a systematic review and meta-analysis. Dementia and geriatric cognitive disorders 33, 297-305 (2012).
- Garcion, E., Wion-Barbot, N., Montero-Menei, C. N., Berger, F. & Wion, D. New clues about vitamin D functions in the nervous system. Trends in Endocrinology & Metabolism 13, 100-105 (2002).
- Brown, J., Bianco, J. I., McGrath, J. J. & Eyles, D. W. 1, 25-Dihydroxyvitamin D(3) induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neuroscience Letters 343, 139-143 (2003).
- Burne, T. H., McGrath, J. J., Eyles, D. W. & Mackay-Sim, A. Behavioural characterization of vitamin D receptor knockout mice. Behavioural brain research 157, 299-308 (2005).
- Kalueff, A. V., Lou, Y.-R., Laaksi, I. & Tuohimaa, P. Impaired motor performance in mice lacking neurosteroid vitamin D receptors. Brain research bulletin 64, 25-29 (2004).
- Zou, J. et al. Progressive hearing loss in mice with a mutated vitamin D receptor gene. Audiology and Neurotology 13, 219-230 (2008).
- Keisala, T. et al. Premature aging in vitamin D receptor mutant mice. The Journal of steroid biochemistry and molecular biology 115, 91-97 (2009).
- Van der Schaft, J. et al. The association between vitamin D and cognition: a systematic review. Ageing research reviews 12, 1013-1023 (2013).
- Sommer, I. et al. Vitamin D deficiency as a risk factor for dementia: a systematic review and meta-analysis. BMC geriatrics 17, 16 (2017).
- Rossom, R. C. et al. Calcium and Vitamin D Supplementation and Cognitive Impairment in the Women's Health Initiative. Journal of the American Geriatrics Society 60, 2197-2205 (2012).
- Dean, A. J. et al. Effects of vitamin D supplementation on cognitive and emotional functioning in young adults-a randomised controlled trial. PloS one 6, e25966 (2011).
- Manders, M. et al. The effect of a nutrient dense drink on mental and physical function in institutionalized elderly people. JNHA-The Journal of Nutrition, Health and Aging 13, 760-767 (2009).
- Stein, M. S., Scherer, S. C., Ladd, K. S. & Harrison, L. C. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer’s disease. Journal of Alzheimer’s Disease 26, 477-484 (2011).
- Annweiler, C. et al. ‘Vitamin D and cognition in older adults’: updated international recommendations. Journal of internal medicine 277, 45-57 (2015).
- Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N. & Davey Smith, G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Statistics in Medicine 27, 1133-1163 (2008).
- Mokry, L. E. et al. Genetically decreased vitamin D and risk of Alzheimer disease. Neurology 87, 2567-2574 (2016).
- Wang, T. J. et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. The Lancet 376, 180-188 (2010).
- Ahn, J. et al. Genome-wide association study of circulating vitamin D levels. Human molecular genetics, ddq155 (2010).
- Berry, D. J., Vimaleswaran, K. S., Whittaker, J. C., Hingorani, A. D. & Hypponen, E. Evaluation of genetic markers as instruments for Mendelian randomization studies on vitamin D. PloS one 7, e37465, https://doi.org/10.1371/journal.pone.0037465 (2012).
- Staiger, D. O. & Stock, J. H. (National Bureau of Economic Research Cambridge, Mass., USA, 1997).
- Annweiler, C. & Beauchet, O. Vitamin D and cognition: recommendations for future trials. Journal of the American Geriatrics Society 61, 1049-1050 (2013).
- Przybelski, R. et al. Rapid correction of low vitamin D status in nursing home residents. Osteoporosis international 19, 1621-1628 (2008).
- Annweiler, C. et al. Cognitive effects of vitamin D supplementation in older outpatients visiting a memory clinic: a pre-post study. Journal of the American Geriatrics Society 60, 793-795 (2012).
- Berry, D. & Hypponen, E. Determinants of vitamin D status: focus on genetic variations. Current opinion in nephrology and hypertension 20, 331-336 (2011).
- Chowdhury, R. et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. (2014).
- Holick, M. F. Vitamin D deficiency. New England Journal of Medicine 357, 266-281 (2007).
- Maddock, J., Geoffroy, M.-C., Power, C. & Hypponen, E. 25-Hydroxyvitamin D and cognitive performance in mid-life. British Journal of Nutrition 111, 904-914 (2014).
- Annweiler, C. et al. Meta-analysis of memory and executive dysfunctions in relation to vitamin D. Journal of Alzheimer’s Disease 37, 147-171 (2013).
596 visitors, last modified 06 Nov, 2017, URL: